Directors' / PDMR dealing
08/12/2025 12:18
RNS Number : 6832K
Futura Medical PLC
08 December 2025
8 December 2025
Futura Medical plc
("Futura" or the "Company")
Directors' / PDMR Dealing
Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, confirms that the following Directors and persons closely associated subscribed for an aggregate of 6,000,000 Ordinary Shares in the Company pursuant to the Fundraise announced on 13 November 2025.
Details are as below:
| Director | Number of New Shares | Issue Price per Ordinary Share | Total number of Ordinary Shares held following Admission | Percentage of Enlarged Share Capital | |
| Alex Duggan* | 5,000,000 | 1 pence | 5,000,000 | 0.86% | |
| Angela Hildreth | 500,000 | 1 pence | 642,857 | 0.11% | |
| Ken James | 500,000 | 1 pence | 799,501 | 0.14% |
| Futura Medical plc | Alex Duggan Chief Executive Officer Angela Hildreth Finance Director and COO | investor.relations@futuramedical.com +44 (0)1483 685 670 www.futuramedical.com |
| Panmure Liberum Nominated Adviser and Broker | Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking) | +44 (0)20 3100 2000 |
| Turner Pope Investments (TPI) Ltd Broker | Guy McDougall / Andrew Thacker | +44 (0) 20 3657 0050 |
| Alma Strategic Communications | Rebecca Sanders-Hewett Sam Modlin Emma Thompson | +44 (0)20 3405 0205 futura@almastrategic.com |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||
| a) | Name | Alex Duggan | ||||||
| 2 | Reason for the notification | |||||||
| a) | Position/status | Chief Executive Officer | ||||||
| b) | Initial notification/Amendment | Initial notification | ||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a) | Name | Futura Medical plc | ||||||
| b) | LEI | 21380053QLT46UNV2303 | ||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares at 0.2p each GB0033278473 | ||||||
| b) | Nature of the transaction | Subscription for ordinary shares | ||||||
| c) | Price(s) and volume(s) |
| ||||||
| d) | Aggregated information - Aggregated volume - Price | 1. 5,000,000 1. £50,000 | ||||||
| e) | Date of the transaction | 4 December 2025 | ||||||
| f) | Place of the transaction | 1. Outside a trading venue | ||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||||||
| a) | Name | Ken James | |||||||||
| 2 | Reason for the notification | ||||||||||
| a) | Position/status | Executive Director and Head of R&D | |||||||||
| b) | Initial notification/Amendment | Initial notification | |||||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||
| a) | Name | Futura Medical plc | |||||||||
| b) | LEI | 21380053QLT46UNV2303 | |||||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares at 0.2p each GB0033278473 | |||||||||
| b) | Nature of the transaction | Subscription for ordinary shares | |||||||||
| c) | Price(s) and volume(s) |
| |||||||||
| d) | Aggregated information - Aggregated volume - Price | 1. 500,000 1. £5,000 | |||||||||
| e) | Date of the transaction | 4 December 2025 | |||||||||
| f) | Place of the transaction | 1. Outside a trading venue | |||||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||||||
| a) | Name | Angela Hildreth | |||||||||
| 2 | Reason for the notification | ||||||||||
| a) | Position/status | FD/COO | |||||||||
| b) | Initial notification/Amendment | Initial notification | |||||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||
| a) | Name | Futura Medical plc | |||||||||
| b) | LEI | 21380053QLT46UNV2303 | |||||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares at 0.2p each GB0033278473 | |||||||||
| b) | Nature of the transaction | Subscription for ordinary shares | |||||||||
| c) | Price(s) and volume(s) |
| |||||||||
| d) | Aggregated information - Aggregated volume - Price | 1. 500,000 1. £5,000 | |||||||||
| e) | Date of the transaction | 4 December 2025 | |||||||||
| f) | Place of the transaction | 1. Outside a trading venue | |||||||||